2m 2m 2m 2m 2m 2m 2m
IRIDEX (IRIX)
NASDAQ
$1.19+$0.02 (+1.28%)
Price as of Jun 03, 2026 5:30 PM EDT- $18.3MMarket Cap
- 21.88%1-Year Change
- Medical DevicesIndustry
IRIDEX (IRIX)
$1.19+$0.02 (+1.28%)
Annual
Quarterly
01/03/2026 | 12/28/2024 | 12/30/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 52.7M +8.23% | 48.7M -6.17% | 51.9M -8.96% | 57.0M +56.74% | |
Cost of Revenue | 33.4M +14.68% | 29.2M -2.98% | 30.1M -4.88% | 31.6M +52.02% | |
Gross Profit | 19.2M -1.41% | 19.5M -10.57% | 21.8M -14.04% | 25.4M +63.05% | |
Sales and Marketing Expense | 10.4M -17.35% | 12.6M -22.53% | 16.2M -10.68% | 18.2M +48.53% | |
Research and Development Expense | -3.7M -32.68% | -5.4M -20.21% | -6.8M -4.82% | -7.2M +118.62% | |
Depreciation and Amortization Expense | 523,000 -10.45% | 584,000 -46.81% | 1.1M +126.39% | 485,000 -3.77% | |
Total Operating Expenses | 21.8M -21.60% | 27.8M -12.60% | 31.8M -3.33% | 32.9M +48.64% | |
Operating Profit | -2.6M -69.03% | -8.3M -17.04% | -10.0M +32.68% | -7.5M +14.57% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -58,000 -60.27% | -146,000 N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | -58,000 -60.27% | -146,000 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | -1.8M +235.00% | -540,000 -202.47% | 527,000 +778.33% | 60,000 -78.57% | |
Income before Taxes | -4.4M -50.46% | -8.8M -6.73% | -9.5M +26.70% | -7.5M +18.71% | |
Income Taxes | 57,000 -16.18% | 68,000 -24.44% | 90,000 +38.46% | 65,000 +150.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -4.4M -50.20% | -8.9M -6.90% | -9.6M +26.81% | -7.5M +19.24% | |
Net Income from Continuing Operations Applicable to Common | -4.4M -50.46% | -8.8M -6.73% | -9.5M +26.70% | -7.5M +18.71% | |
Basic EPS and Net Income | -0.26 -51.85% | -0.54 -8.47% | -0.59 +25.53% | -0.47 +2.17% | |
Diluted EPS and Net Income | -0.26 -51.85% | -0.54 -8.47% | -0.59 +25.53% | -0.47 +2.17% | |
Basic Weighted Average Shares | 16.9M +3.01% | 16.4M +1.93% | 16.1M +1.19% | 15.9M +15.14% | |
Diluted Weighted Average Shares | 16.9M +3.01% | 16.4M +1.93% | 16.1M +1.19% | 15.9M +15.14% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 6.0M +152.53% | 2.4M -66.06% | 7.0M -49.48% | 13.9M +19.75% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 6.0M +152.53% | 2.4M -66.06% | 7.0M -49.48% | 13.9M +19.75% | |
Total Current Assets | 25.3M +7.17% | 23.6M -14.16% | 27.4M -23.25% | 35.8M +41.04% | |
Accumulated Depreciation | 14.2M +1.43% | 14.0M +1.77% | 13.7M +1.33% | 13.6M +6.14% | |
Property and Plant and Equipment and Net | 58,000 -49.57% | 115,000 -67.24% | 351,000 -24.03% | 462,000 +2.90% | |
Total Long-Term Assets | 1.1M -19.37% | 1.4M -0.14% | 1.4M -4.05% | 1.5M +1,002.27% | |
Total Assets | 29.2M +0.05% | 29.1M -15.39% | 34.4M -18.57% | 42.3M +51.20% | |
Income Taxes Payable | 31,000 -79.33% | 150,000 +50.00% | 100,000 +53.85% | 65,000 N/A | |
Total Short-Term Debt | 0 -100.00% | 1.7M N/A | 0 N/A | 0 -100.00% | |
Total Current Liabilities | 13.2M -20.24% | 16.6M +27.63% | 13.0M +4.18% | 12.5M +43.45% | |
Total Long-Term Debt | 3.7M +272.01% | 1.0M N/A | N/A N/A | 1.2M 0.00% | |
Total Long-Term Liabilities | 387,000 +23.25% | 314,000 +1,107.69% | 26,000 0.00% | 26,000 +18.18% | |
Total Liabilities | 24.2M -10.39% | 27.0M +8.53% | 24.9M -0.58% | 25.1M +136.34% | |
Retained Earnings | -92.4M +5.04% | -88.0M +11.34% | -79.0M +13.38% | -69.7M +22.43% | |
Total Stockholders Equity | 4.9M +134.72% | 2.1M -77.98% | 9.5M -44.74% | 17.2M -0.78% | |
Total Shares Outstanding | 17.3M +4.03% | 16.6M +2.36% | 16.3M +1.65% | 16.0M +15.04% | |
Cash Flow | |||||
Cash from Operating Activities | -2.1M -70.97% | -7.3M +8.01% | -6.7M -29.14% | -9.5M +194.07% | |
Capital Expenditures | 143,000 +1,000.00% | 13,000 -88.07% | 109,000 -61.89% | 286,000 +194.85% | |
Cash from Investing Activities | -143,000 +1,000.00% | -13,000 -88.07% | -109,000 -61.89% | -286,000 +207.53% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 6.0M +128.94% | 2.6M +52,200.00% | -5,000 -93.15% | -73,000 -102.96% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | 40.07% -4.69% | 42.04% -5.58% | 44.53% N/A | |
Operating Margin | N/A N/A | -17.06% -11.58% | -19.29% +45.74% | -13.24% N/A | |
Return on Assets | N/A N/A | -28.03% +12.37% | -24.95% +16.12% | -21.48% N/A | |
Return on Equity | N/A N/A | -153.37% +114.37% | -71.54% +63.98% | -43.63% N/A | |
Revenue Growth | N/A N/A | -6.17% -31.12% | -8.96% -115.78% | 56.74% N/A | |
Current Ratio | N/A N/A | 1.42 -32.75% | 2.12 -26.33% | 2.87 N/A | |
Cash Ratio | N/A N/A | 0.14 -73.40% | 0.54 -51.50% | 1.12 N/A | |
Debt-to-Equity Ratio | N/A N/A | 1.31 N/A | N/A N/A | 0.07 N/A | |
Debt-to-Assets Ratio | N/A N/A | 0.09 N/A | N/A N/A | 0.03 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow